“Understand that we are the only ones capable of doing this task, because we’ve cared from the very beginning, because we have the capabilities, and because we can bring all the pieces together. So...
The article, written by María Iglesias, Digital & IT Head at Viralgen, explores how digitalization has transformed the manufacturing processes of adeno-associated viral (AAV) vectors at the company....
Last week we had the opportunity to host Sonia Guirado, a member of the Eurofirms Foundation and a renowned Paralympic medalist of the Barcelona '92 and Atlanta '96 Games. During her talk, Sonia...
Viralgen Vector Core, S.L. ha obtenido una vez más apoyo desde el Gobierno Vasco a través del Programa Bilakatu de Ayuda a empresas afectadas por el Covid-19 – Convocatoria 2022. Esta iniciativa está...
Viralgen Vector Core, S.L. ha obtenido una vez más apoyo desde el Gobierno Vasco a través del Programa Bilakatu de Ayuda a empresas afectadas por el Covid-19 – Convocatoria 2022. Esta iniciativa está...
VIRALGEN VECTOR CORE, S.L. has secured vital support from the HAZITEK Business R&D Support Program of the Basque Government-Call 2023. This collaborative initiative, backed by the European Regional...
ASGCT 26th Annual Meeting starts in a few days. This year, it will be held in Los Angeles from May 16 to 20, and Viralgen will be present at booth 123.
Rare Disease Day is the globally coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare...
Visit us at Phacilitate Advanced Therapies Week in Miami, January 17 – 20, 2023, Booth 425. Hear about our recent successes, including our commercial inspection and 2,000L GMP scale AAV...
Viralgen is happy to kick off the new year at JPM 2023! Come and join us at a special reception we are hosting at JP Morgan Tuesday evening, January 10.